Phenotype / cell stem origin
The progenitor cell from which Barrett's oesophagus develops is still unclear. Progenitor cells resident in the submucosal glands or the interbasal layer of the epithelium, bone-marrow-derived stem cells, or transdifferentiated squamous cells are included in the candidate cells.
Etiology
Gastroesophageal reflux disease (GERD) is considered the major risk factor for Barrett's esophagus. About 1 in 10 patients with GERD are found to have Barrett's esophagus. GERD generates reactive oxygen species that produce oxidative stress and subsequent oxidative DNA damage. Some DNA damage may cause DNA mutations that accumulate and cause tumor formation.
Epidemiology
Barrett's esophagus is more common in men than in women, with a male:female ratio of about 2:1. The risk factors of Barrett's esophagus include Age (increasing with age), Race (more common in Caucasians), smoking (not clear), alcohol consumption (not clear), gastroesophageal reflux disease (GERD, major factor), and obesity. On the other hand, some controversial reports indicate that H. pylori infection and the virulent cagA strains in particular, may protect against the development of Barrett's oesophagus and progression to adenocarcinoma.
Normal esophagus is covered by squamous epithelia (A). However, in Barrett's esophagus (B), the squamous epithelia are replaced by intestinalized metaplastic columnar epithelia.
Disease
Barrett's dysplasia Note Barrett's dysplasia is defined morphologically as unequivocal neoplastic epithelium that remains confined within the basement membrane of the epithelium from which it developed. In patients with Barrett's esophagus, dysplasia is graded as either low or high, depending on its cytological and architectural features.
Epidemiology
Most Barrett's esophagus never progress to dysplasia and carcinoma. It has been reported that the male gender, longstanding gastroesophageal reflux disease, hiatal hernia size, and segment length are strongly associated with Barrett's dysplasia. On the other hand, successful antireflux surgery protects the Barrett's mucosa from developing high-grade dysplasia and esophageal adenocarcinoma. and segment length are strongly associated with adenocarcinoma, Barrett's esophagus with dysplasia is likely the true precursor for developing to adenocarcinoma.
Disease

Clinics
Heartburn is the most common symptom of GERD and Barrett's esophagus. As for Barrett's adenocarcinoma, it shares the symptoms with other esophageal type cancers, such as difficulty swallowing, unexplained weight loss, pain in the throat or mid-chest, etc.
Pathology
There is no difference in the term of histology of Barrett's adenocarcinoma from that in the stomach and colon. It can be graded into well-, moderately-and poorly-differentiated adenocarcinoma based on their cytologic and architectural atypia. The Lauren classification for gastric cancer has also been used by some pathologists and physicians to divide into either intestinal or diffuse histological type.
Treatment
Esophagectomy is still the most common primary treatment. Other treatment modalities include chemotherapy, radiation therapy, stents, photodynamic therapy, and endoscopic therapy with an Nd:YAG laser. Combined modality therapy (i.e., chemotherapy plus surgery or chemotherapy and radiation therapy plus surgery) is under clinical evaluation.
Prognosis
The prognosis of Barrett's adenocarcinoma depends on the stage at diagnosis, treatment and the patients' general condition. The overall 5-year survival rate in patients amenable to definitive treatment ranges from 5 to 30%.
Cytogenetics
Note
The chromosomal alterations most frequently identified in Barrett's adenocarcinoma by CGH were: gains in 8q (80%), 20q (60%); 2p, 7p and 10q (47% each), 6p (37%), 15q (33%), and 17q (30%). Losses were observed predominantly in the 4q (50%); 5q and 9p (43% each), 18q (40%), 7q (33%), and 14q (30%).
Genes involved and proteins
Note
There are many genes that have been reported to be genetically and/or epigenetically dysregulated, such as gene mutation, amplification, and LOH and DNA methylation that involved cell cycle control, apoptosis, cell adhesion and antioxidative stress, etc. Some representative genes are described below.
ERBB2 (HER2/neu)
Location 17q21 Note ERBB2 protein over-expression and/or DNA amplification have been reported in 10-70% of esophageal adenocarcinomas. The present literature data suggest that ERBB2 overexpression may be a late event in the dysplasia-carcinoma sequence, as it occurred predominantly in high-grade dysplasia and adenocarcinomas.
CGH analysis of a case of Barrett's esophageal adenocarcinoma. Tumor DNA was labeled with FITC (Green) and reference DNA was labeled with TRITC (red). The hybridizations were analyzed using an Olympus fluorescence microscope and the ISIS digital image analysis system (Metasystems GmbH, Altlussheim, Germany) based on integrated high-sensitivity monochrome CCD camera and automated CGH analysis software. The green colon indicates areas of DNA gains whereas the red color indicates DNA losses in the tumor sample.
It has been reported that ERBB2 overexpression/amplification in carcinoma correlated significantly with tumor invasion, lymph node metastasis, and poor prognosis in patients with Barrett's related adenocarcinoma. Protein The ERBB2 (also called HER2 or NEU) gene encodes an integral type I protein of 185 kDa, 1255 amino acids, with a cysteine-rich extracellular ligand-binding domain, a transmembrane domain and an intracellular region endowed with a tyrosine kinase activity.
C-MYC
Location 8q24 Note Frequent high-level chromosomal amplification of 8q21 has been reported in Barrett's adenocarcinoma and c-myc is the potential target gene for this amplification. It has been reported that amplification of c-myc was detected in 25% of high-grade dysplasia and 44% of adenocarcinomas, but in none of Barrett's metaplasia and low-grade dysplasia. Protein DNA binding protein with 439 amino acids and 48 kDa (p64); 454 amino acids (p67, 15 additional amino acids in N-term), contains a transactivation domain, an acidic domain, a nuclear localization signal, a basic domain, a helix-loop-helix motif, and a leucin zipper.
CDX1
Location 5q33.1 Note CDX1 is predominantly expressed in the small intestine and colon, but not in normal esophageal squamous epithelia or gastric epithelia. CDX1 was over-expressed in Barrett's esophagus and adenocarcinomas, most likely through promoter DNA hypomethylation. Protein Member of the caudal-related homeobox transcription factor gene family. The encoded protein regulates intestine-specific gene expression and differentiation of intestine.
CDX2
Location 13q12.2 Note CDX2 is predominantly expressed in the small intestine and colon, but not in normal esophageal squamous epithelia or gastric epithelia. CDX2 expression is observed in the intestinal metastasis area.
Protein
Member of the caudal-related homeobox transcription factor gene family. The encoded protein regulates intestine-specific gene expression and differentiation of intestine. It is suggested that CDX2 is a "master switch" gene whose normal expression determines the proximal and distal specialization of the gut in embryogenesis. 
CDKN2A (p16)
TP53
Location 17p13 Note Loss of p53 occurs through either LOH, sequence mutation, or both. Loss of p53 has been reported in Barrett's esophagus and likely correlates with progression to adenocarcinoma, as patients with LOH in TP53 are 16 times more likely to progress to adenocarcinoma than patients without TP53 LOH. DNA / RNA Exon Count: 11. Protein A tumor suppressor protein essential in cell cycle regulation and in DNA damage repair. p53 transcriptionally regulates multiple genes functioning as an inhibitor of cell growth and proliferation and inducer of apoptosis. Loss of TP53 functions promotes tumor progression, most likely by preventing cell cycle arrest, suppressing apoptosis and permitting genetic instability for subsequent genetic alterations.
CDKN1B (p27)
Location 12p13 Note It has been reported that in 83% of Barrett's adenocarcinomas, p27 protein was down-regulated by an immunohistochemical study. And for p27 to arrest cell cycle, it must localize in the nucleus. However, in approximately 50% of high-grade dysplasia, p27 was observed in cytoplasmic localization, which renders it inactive. Protein A tumor suppressor protein essential in cell cycle regulation, a CDK inhibitor.
GPX3
Location 5q33.1 Note GPX3 is one of the glutathione peroxidase family members, which functions in the detoxification of hydrogen peroxide. Frequent GPX3 gene promoter hypermethylation has recently been demonstrated in Barrett's adenocarcinomas and its precancerous lesions, Barrett's esophagus and dysplasia, and was significantly associated with gene down-regulation. It is noted that GPX3 has been recently reported as a potential tumor suppressor in prostatic carcinomas. Protein GPX3 is a secretory protein. 
GPX7
Protein
Adenomatous polyposis coli protein which possesses tumor suppressor functions, works as an antagonist of the Wnt signaling pathway. APC binding to beta catenin leads to ubiquitin-mediated beta catenin destruction; loss of APC function increases transcription of beta catenin targets, such as C-MYC and Cyclin D. It is also involved in other processes including cell migration and adhesion, transcriptional activation, and apoptosis. Germline defects in this gene cause familial adenomatous polyposis (FAP), an autosomal dominant pre-malignant disease that usually progresses to malignancy. Disease-associated mutations tend to be clustered in a small region designated the mutation cluster region (MCR) and result in a truncated protein product.
